Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.49 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141723 | 0.92 | MAPK14 (0.47) | MAPK14MAPK11FASN | |
| SCHEMBL3148925 | 0.90 | MAPK14 (0.51) | MAPK14TTK | |
| SCHEMBL3140560 | 0.89 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL3141584 | 0.88 | MAPK14 (0.48) | MAPK14 | |
| SCHEMBL3148553 | 0.88 | MAPK14 (0.54) | MAPK14TTK | |
| SCHEMBL3149778 | 0.87 | MAPK14 (0.48) | MAPK14 | |
| SCHEMBL3148770 | 0.87 | MAPK14 (0.50) | MAPK14MAPK11 | |
| SCHEMBL3148818 | 0.87 | MAPK14 (0.52) | MAPK14MAPK11 | |
| SCHEMBL3148880 | 0.86 | MAPK14 (0.49) | MAPK14TTK | |
| SCHEMBL3150029 | 0.86 | MAPK14 (0.54) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699800-B1 | BICYCLIC HETEROCYCLIC P-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-02-10 | — | — | EP | claimed |
| US-20090264409-A1 | Bicyclic Heterocyclic p-38 Kinase Inhibitors | DONG QING | 2009-10-22 | — | — | US | disclosed |
| US-20090264409-A1 | Bicyclic Heterocyclic p-38 Kinase Inhibitors | DONG QING | 2009-10-22 | — | — | US | disclosed |
| US-20090264409-A1 | Bicyclic Heterocyclic p-38 Kinase Inhibitors | DONG QING | 2009-10-22 | — | — | US | disclosed |
| US-7569571-B2 | Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-20070142405-A1 | Such as N-cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide; for inhibiting p38 kinase mediated diseases and disorders such as inflammatory diseases | TRIAD THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142405-A1 | Such as N-cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide; for inhibiting p38 kinase mediated diseases and disorders such as inflammatory diseases | TRIAD THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142405-A1 | Such as N-cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide; for inhibiting p38 kinase mediated diseases and disorders such as inflammatory diseases | TRIAD THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264409-A1 | Bicyclic Heterocyclic p-38 Kinase Inhibitors | MAPK8, MAP3K8, MAPKAPK2 | MAPK14 35/4885DNPH1 4720/4885MAPK11 43/4885 |
| US-20070142405-A1 | Such as N-cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide; for inhibiting p38 kinase mediated diseases and disorders such as inflammatory diseases | MAPK1, MAP3K8, MAP3K1 | MAPK14 33/4885DNPH1 4293/4885MAPK11 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.